Syndesi Therapeutics

Chemin Du Cyclotron 6

1348 Ottignies-Louvain-La-Neuve

BE

Syndesi Therapeutics

Foundation date

19/12/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.

Upcoming events

Latest news

  • Latest field trials validate strength of Biotalys’ first biocontrol Evoca

    Thursday May 19th 2022

  • Belgian biotech in European Top-3 despite turbulent times

    Wednesday May 18th 2022

  • KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus

    Wednesday May 18th 2022